ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals (Nasdaq: ORIC) announced that preclinical data for ORIC-944, their PRC2 inhibitor for prostate cancer treatment, will be presented at the 2025 AACR Annual Meeting in Chicago (April 25-30, 2025).
The preclinical results show ORIC-944 as a potent, selective, and orally bioavailable allosteric PRC2 inhibitor with properties supporting once-daily dosing. The drug demonstrated robust PRC2 inhibition in prostate cancer models, enhancing luminal cell state and increasing androgen receptor (AR) signaling. The treatment restricts cellular plasticity and creates an AR-dependent state, showing synergy with AR pathway inhibitors (ARPIs) in both ARPI-sensitive and resistant settings.
A phase 1b trial combining ORIC-944 with ARPIs is currently ongoing in metastatic prostate cancer (NCT05413421).
ORIC Pharmaceuticals (Nasdaq: ORIC) ha annunciato che i dati preclinici per ORIC-944, il loro inibitore PRC2 per il trattamento del cancro alla prostata, saranno presentati al 2025 AACR Annual Meeting a Chicago (25-30 aprile 2025).
I risultati preclinici mostrano ORIC-944 come un potente, selettivo e bio disponibile per via orale inibitore allosterico di PRC2, con caratteristiche che supportano una somministrazione una volta al giorno. Il farmaco ha dimostrato una robusta inibizione di PRC2 nei modelli di cancro alla prostata, migliorando lo stato delle cellule luminali e aumentando il segnale del recettore degli androgeni (AR). Il trattamento limita la plasticità cellulare e crea uno stato dipendente da AR, mostrando sinergia con gli inibitori della via AR (ARPIs) sia in contesti sensibili che resistenti agli ARPI.
Attualmente è in corso uno studio di fase 1b che combina ORIC-944 con ARPIs nel cancro alla prostata metastatico (NCT05413421).
ORIC Pharmaceuticals (Nasdaq: ORIC) anunció que los datos preclínicos de ORIC-944, su inhibidor de PRC2 para el tratamiento del cáncer de próstata, se presentarán en la Reunión Anual AACR 2025 en Chicago (25-30 de abril de 2025).
Los resultados preclínicos muestran que ORIC-944 es un potente, selectivo y bio disponible por vía oral inhibidor alostérico de PRC2, con propiedades que respaldan la dosificación una vez al día. El fármaco demostró una robusta inhibición de PRC2 en modelos de cáncer de próstata, mejorando el estado de las células luminales y aumentando la señalización del receptor de andrógenos (AR). El tratamiento restringe la plasticidad celular y crea un estado dependiente de AR, mostrando sinergia con los inhibidores de la vía AR (ARPIs) tanto en contextos sensibles como resistentes a ARPI.
Actualmente se está llevando a cabo un ensayo de fase 1b que combina ORIC-944 con ARPIs en cáncer de próstata metastásico (NCT05413421).
ORIC Pharmaceuticals (Nasdaq: ORIC)는 전립선암 치료를 위한 PRC2 억제제 ORIC-944의 전임상 데이터가 2025 AACR 연례 회의에서 시카고(2025년 4월 25-30일)에서 발표될 것이라고 발표했습니다.
전임상 결과는 ORIC-944가 강력하고 선택적이며 경구 생체이용 가능한 알로스테릭 PRC2 억제제로, 하루 한 번 복용할 수 있는 특성을 가지고 있음을 보여줍니다. 이 약물은 전립선암 모델에서 강력한 PRC2 억제를 나타내며, 세포의 내강 상태를 개선하고 안드로겐 수용체(AR) 신호를 증가시킵니다. 이 치료는 세포의 가소성을 제한하고 AR 의존 상태를 생성하며, AR 경로 억제제(ARPIs)와의 시너지를 보여줍니다. 이는 ARPI에 민감한 환경과 저항성 환경 모두에서 나타납니다.
현재 ORIC-944와 ARPIs를 결합한 1b상 임상이 전이성 전립선암에서 진행 중입니다 (NCT05413421).
ORIC Pharmaceuticals (Nasdaq: ORIC) a annoncé que des données précliniques pour ORIC-944, leur inhibiteur de PRC2 pour le traitement du cancer de la prostate, seront présentées lors de la Réunion Annuelle AACR 2025 à Chicago (du 25 au 30 avril 2025).
Les résultats précliniques montrent qu'ORIC-944 est un inhibiteur allostérique de PRC2 puissant, sélectif et bio-disponible par voie orale, avec des propriétés soutenant une posologie une fois par jour. Le médicament a démontré une inhibition robuste de PRC2 dans des modèles de cancer de la prostate, améliorant l'état des cellules luminales et augmentant la signalisation du récepteur aux androgènes (AR). Le traitement limite la plasticité cellulaire et crée un état dépendant des AR, montrant une synergie avec les inhibiteurs de la voie AR (ARPIs) tant dans des contextes sensibles que résistants aux ARPI.
Un essai de phase 1b combinant ORIC-944 avec des ARPIs est actuellement en cours dans le cancer de la prostate métastatique (NCT05413421).
ORIC Pharmaceuticals (Nasdaq: ORIC) gab bekannt, dass präklinische Daten zu ORIC-944, ihrem PRC2-Inhibitor zur Behandlung von Prostatakrebs, auf dem 2025 AACR Annual Meeting in Chicago (25.-30. April 2025) präsentiert werden.
Die präklinischen Ergebnisse zeigen, dass ORIC-944 ein potenter, selektiver und oral bioverfügbarer allosterischer PRC2-Inhibitor ist, der Eigenschaften aufweist, die eine einmal tägliche Dosierung unterstützen. Das Medikament zeigte eine robuste PRC2-Hemmung in Prostatakrebsmodellen, verbesserte den luminalen Zellzustand und erhöhte die Androgenrezeptor (AR)-Signalgebung. Die Behandlung schränkt die zelluläre Plastizität ein und schafft einen AR-abhängigen Zustand, der in sowohl ARPI-sensitiven als auch resistenten Umgebungen Synergien mit AR-Weg-Inhibitoren (ARPIs) zeigt.
Derzeit läuft eine Phase-1b-Studie, die ORIC-944 mit ARPIs bei metastasierendem Prostatakrebs kombiniert (NCT05413421).
- Phase 1b clinical trial ongoing for ORIC-944 in metastatic prostate cancer
- Demonstrated synergistic effects with AR pathway inhibitors in both ARPI-sensitive and resistant settings
- Drug properties support convenient once-daily dosing regimen
- Still in early clinical development phase with only preclinical data available
- Efficacy in human subjects yet to be demonstrated
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that a preclinical abstract highlighting the potential of ORIC-944, a potent and selective allosteric inhibitor of PRC2 to treat prostate cancer, has been accepted for poster presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30, 2025 in Chicago, IL.
Poster presentation details:
| Title: | ORIC-944, a PRC2 inhibitor with best-in-class properties, restores luminal features and restricts adaptation in prostate cancer models, conferring synergy with AR pathway inhibitors |
| Abstract Number: | 452 |
| Date & Time: | Sunday, April 27, 2025, 2:00 – 5:00 p.m. CT |
| Session Category: | Experimental and Molecular Therapeutics |
| Session Title: | Epigenetic Targets |
| Location: | Poster Section 20 |
Abstract Highlights
ORIC-944 is a potent, highly selective, orally bioavailable, allosteric inhibitor of PRC2 that demonstrates best-in-class drug properties, including potency, solubility, and pharmacokinetics, with half-life supporting once daily dosing. In preclinical prostate cancer models, ORIC-944 demonstrated robust inhibition of PRC2, enhanced luminal cell state, and increased androgen receptor (AR) signaling. Analysis of chromatin revealed that ORIC-944 specifically restricts accessibility to lineage-associated transcription factors known to impart cellular plasticity in prostate cancer. This plasticity-restricted luminal state conferred by PRC2 inhibition is dependent on AR, leading to antitumor activity either in the hormone-depleted context or in the combination setting with an AR pathway inhibitor (ARPI). Together these data indicate that ORIC-944 reinforces a luminal cell state and, notably, restricts access to plasticity genes leading to a highly AR-dependent state in prostate models. This mechanism supports the observed preclinical synergy between PRC2 inhibition and ARPIs in both ARPI-sensitive and ARPI-resistant settings. These results position ORIC-944 as a potential best-in-class PRC2 inhibitor that blocks prostate tumor adaptation, restores luminal features, and sensitizes tumors to ARPIs. A phase 1b trial of ORIC-944 in combination with ARPIs is ongoing in metastatic prostate cancer (NCT05413421).
All regular abstracts are available for viewing via AACR’s online itinerary planner located, here.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the continued clinical development of ORIC-944; statements regarding the potential best-in-class properties of ORIC-944; the potential advantages of ORIC-944 and ORIC’s other programs; and plans underlying ORIC’s clinical trials and development. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC’s product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements or its clinical trial collaboration and supply agreements; the potential market for ORIC’s product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section titled “Risk Factors” in ORIC’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 18, 2025, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
What are the key preclinical findings for ORIC-944 in prostate cancer treatment?
What is the current development stage of ORIC-944 as of March 2025?
What are the key drug properties of ORIC's ORIC-944?
When and where will ORIC present the ORIC-944 preclinical data?
